Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-1380
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism ; volume:6 ; number:1 ; day:16 ; month:7 ; year:2013 ; pages:1-9 ; date:12.2013
International journal of emergency medicine ; 6, Heft 1 (16.7.2013), 1-9, 12.2013
- Creator
-
Goldstein, Patrick
Elalamy, Ismaïl
Huber, Kurt
Danchin, Nicolas
Wiel, Eric
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1865-1380-6-25
- URN
-
urn:nbn:de:101:1-2019062923430023891267
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Goldstein, Patrick
- Elalamy, Ismaïl
- Huber, Kurt
- Danchin, Nicolas
- Wiel, Eric
- SpringerLink (Online service)
Other Objects (12)
Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
Coagulation testing in intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants
Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
Rivaroxaban versus vitamin K antagonist treatment on the progression of coronary calcification: the IRIVASC-trial
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis
Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
Coagulation testing in intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants
Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
Rivaroxaban versus vitamin K antagonist treatment on the progression of coronary calcification: the IRIVASC-trial
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis
Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
Coagulation testing in intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants
Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
Rivaroxaban versus vitamin K antagonist treatment on the progression of coronary calcification: the IRIVASC-trial
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients